Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3–tyrosine kinase domain mutations

Author： Alvarado Yesid   Kantarjian Hagop M.   Luthra Rajyalakshmi   Ravandi Farhad   Borthakur Gautam   Garcia-Manero Guillermo   Konopleva Marina   Estrov Zeev   Andreeff Michael   Cortes Jorge E.  

Publisher： Blackwell Publishing

E-ISSN： 1097-0142|120|14|2142-2149

ISSN： 0008-543X

Source： Cancer, Vol.120, Iss.14, 2014-07, pp. : 2142-2149

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

The clinical development of FLT3 inhibitors in acute myeloid leukemia

By Knapper Steven  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 10, 2011-10 ,pp. : 1377-1395

Informa Healthcare

Access to resources Recommend Favorite

Flt3 Receptor Tyrosine Kinase as a Drug Target in Leukemia

By  

Current Pharmaceutical Design, Vol. 10, Iss. 16, 2004-06 ,pp. : 1867-1883

Bentham Science Publishers

Access to resources Recommend Favorite

Novel FLT3 tyrosine kinase inhibitors

By Levis Mark   Small Donald  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 12, 2003-12 ,pp. : 1951-1962

Informa Healthcare

Access to resources Recommend Favorite

Small Molecule FLT3 Tyrosine Kinase Inhibitors

By  

Current Pharmaceutical Design, Vol. 10, Iss. 11, 2004-04 ,pp. : 1183-1193

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting FLT3 Kinase in Acute Myelogenous Leukemia: Progress, Perils, and Prospects

By  

Mini Reviews in Medicinal Chemistry, Vol. 4, Iss. 3, 2004-03 ,pp. : 255-271

Bentham Science Publishers

Access to resources Recommend Favorite